UNSPSC 51171510: Magnesium trisilicate

This classification denotes an antacid preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2E1CI501T. European Medicines Agency schedules Magnesium trisilicate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14451MIG. Magnesium trisilicate generally arises in the molecular formula 2MG.O8SI3.H2O. The term 'magnesium trisilicate' is a European Pharmacopoeia designation. As of Q4 2014, MAGNESIUM TRISILICATE remains the US FDA Preferred Term for this commodity.

Magnesium trisilicate bears US NLM identifiers UMLS ID C0065533 and NCI Concept Code C66052. SMILES: [O-][SI](=O)O[SI]([O-])([O-])O[SI](=O)[O-].[MG+2].[MG+2].

UNSPSC 51171510 Magnesium trisilicate is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three opportunities tagged under this code — offender drug testing services (Collin County), a pharmacy benefit manager direct-to-manufacturer RFI (Texas HHS Commission), and generic pharmaceutical and OTC product supply (Minnesota Multistate Cooperative Purchasing Alliance) — do not involve magnesium trisilicate or antacid active pharmaceutical ingredients in any documented scope. The code appears to be a mislabeling artifact rather than a category under which state and local governments are actively procuring this specific chemical compound. No recent solicitations for magnesium trisilicate itself are present in the available opportunities block.

The geographic activity that does appear under this code tag spans Texas (Collin County and Texas HHS Commission) and Minnesota (MMCAP), though the actual work being solicited — drug testing staffing and lab operations, pharmacy benefit contracting, and multi-source generic pharmaceutical sourcing — falls outside the pharmaceutical intermediate or active ingredient space that the code nominally describes. A business development professional evaluating pursuit under this code should treat it as dormant for state and local procurement purposes and verify whether magnesium trisilicate opportunities exist under different UNSPSC classifications or through direct outreach to health departments, corrections agencies, and institutional pharmaceutical buyers that might stock antacid formulations.